Zoetis (NYSE:ZTS) issued an update on its FY18 earnings guidance on Thursday morning. The company provided EPS guidance of $2.96-3.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.98. The company issued revenue guidance of $5.675-5.8 billion, compared to the consensus revenue estimate of $5.62 billion.
Shares of Zoetis (NYSE:ZTS) opened at $76.79 on Thursday. Zoetis has a 52 week low of $52.00 and a 52 week high of $80.13. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $35,688.99, a P/E ratio of 39.19, a PEG ratio of 1.62 and a beta of 1.07.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. Zoetis’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.47 earnings per share. research analysts forecast that Zoetis will post 2.36 EPS for the current fiscal year.
Several research analysts have issued reports on ZTS shares. Cowen set a $80.00 price objective on Zoetis and gave the stock a buy rating in a research report on Friday, November 17th. Jefferies Group reiterated a buy rating on shares of Zoetis in a research report on Friday, November 10th. BidaskClub upgraded Zoetis from a hold rating to a buy rating in a research report on Tuesday, November 7th. Cantor Fitzgerald reiterated a buy rating and issued a $75.00 price objective on shares of Zoetis in a research report on Tuesday, October 24th. Finally, Stifel Nicolaus reiterated a buy rating and issued a $65.00 price objective on shares of Zoetis in a research report on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $73.72.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.